Piper Sandler maintains Overweight rating on Colgate stock

Piper Sandler reaffirmed its Overweight rating on Colgate-Palmolive (CL) with a $109 price target, citing effective tariff management and geographic strengths, despite InvestingPro analysis indicating the stock is trading above fair value. This endorsement follows discussions with Colgate's CEO regarding the company's performance and outlook amid tariff challenges; however, Colgate-Palmolive reported mixed Q1 2025 results, with revenue exceeding expectations at $4.91 billion but EPS missing at $0.85, while Goldman Sachs maintains a Buy rating with a $106 target, highlighting the growth potential of Hill's Pet Nutrition.

Analysis

Piper Sandler has reaffirmed its Overweight rating and $109.00 price target for Colgate-Palmolive (NYSE:CL), indicating an 18% potential upside, following discussions with company management that emphasized effective tariff management and strong geographic operations. This contrasts with InvestingPro's analysis suggesting the stock trades above its Fair Value, despite acknowledging Colgate-Palmolive's GOOD financial health and impressive gross profit margins of 60.81%. The company's Q1 2025 financial results were mixed: earnings per share (EPS) of $0.85 narrowly missed the $0.87 forecast, while revenue of $4.91 billion exceeded the $4.89 billion expectation, reflecting robust sales. The Hill’s Pet Nutrition segment remains a significant growth catalyst, supporting a Buy rating and a $106.00 price target from Goldman Sachs, which anticipates mid-single-digit organic sales growth for the division. Colgate-Palmolive is addressing an expected $200 million annual cost impact from tariffs through productivity and innovation, and plans to exit the private label business by Q3 2025, alongside ongoing investments in its supply chain. Management anticipates top-line improvement in the latter half of 2025, with a strategic focus on North America, Asia, and Africa Eurasia.

Key Decisions for Investors

• Investors should consider the positive analyst outlook from Piper Sandler and Goldman Sachs, driven by strong fundamentals like high gross margins and growth in Hill's Pet Nutrition, while also noting the valuation concern highlighted by InvestingPro and the recent Q1 EPS miss.
• Monitor the company's execution on its strategies to mitigate the $200 million tariff impact and the successful exit from the private label business, as these are key to maintaining profitability.
• Closely evaluate revenue trends and management's ability to achieve projected top-line improvements in the second half of 2025, particularly in designated key markets, to confirm the continued operational strength and growth trajectory.